Skip to main content

Kaveh Ardalan

Assistant Professor of Pediatrics
Pediatrics, Rheumatology

Overview


Dr. Ardalan's clinical interests are in juvenile myositis, lupus, and scleroderma and he is co-director of the Duke Children's Myositis Center.  He also co-leads the Duke Pediatric Lupus Clinic.  Dr. Ardalan's research interests encompass health-related quality of life, patient-reported outcomes, mental health, psychological stress, adverse childhood experiences, cardiovascular health and outcomes research, psychometrics, and qualitative/mixed methods research. His most recent work, funded by the Rheumatology Research Foundation Investigator Award, focuses on the relationships between psychological stress, inflammation, and cardiovascular health in juvenile lupus and dermatomyositis.

Current Appointments & Affiliations


Assistant Professor of Pediatrics · 2021 - Present Pediatrics, Rheumatology, Pediatrics

In the News


Published May 27, 2025
How Living with Childhood-Onset Lupus Impacts Mental Health
Published May 2, 2025
ACR, CARRA Issue First-Ever Pediatric Rheumatology Mental Health Guidance
Published March 27, 2023
Anifrolumab Shows Promise in Refractory Discoid Lupus Erythematosu

View All News

Recent Publications


Remission and low disease activity definitions in adult idiopathic inflammatory myopathies: A narrative review by myositis clinical trials consortium (MCTC).

Journal Article Autoimmun Rev · September 24, 2025 Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare systemic autoimmune rheumatic diseases. Despite advances in treatment, the definition of remission and low disease activity (LDA) in IIM remains inconsistent and lacks consensus and ... Full text Link to item Cite

Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers.

Journal Article Rheumatology (Oxford) · August 1, 2025 OBJECTIVES: Janus kinase inhibition (JAKi) has been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signalling. Predominantly retrospective reports have demonstrated effectiveness of JAKi in refractory JDM. How ... Full text Link to item Cite

CAR T cell therapy for children with rheumatic disease: the time is now.

Journal Article Nat Rev Rheumatol · August 2025 Initial success with B cell-targeted chimeric antigen receptor (CAR) T cells for the treatment of systemic lupus erythematosus and other rheumatic diseases has generated enthusiasm for the broad application of this technology outside of the field of oncolo ... Full text Link to item Cite
View All Publications

Education, Training & Certifications


University of Virginia, School of Medicine · 2009 M.D.